---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-043497"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:00:41.247802+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma announces $10M PIPE (up to $60M with warrants) to fund UK flu challenge trial

## Summary
- Upfront gross proceeds of $10M from sale of ~5.98M shares at $1.6730/share; warrants could add $50M.
- Proceeds to advance influenza program tivoxavir marboxil through Phase 2a human challenge trial in UK.
- Warrant tranches: Series A ($10M upon MHRA approval), Series B ($10M post-data + shareholder OK), Series C ($30M, 3-year term).
- Lead investor Sirenia Capital Management; Cantor Fitzgerald lead placement agent; closing expected April 16, 2026.
- Company to file resale registration statement within 30 days of closing; shareholder meeting required for Series B/C warrants.

## SEC filing metadata
- accession: 0001104659-26-043497
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465926043497/0001104659-26-043497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465926043497/tm2611843d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-043497
- JSON: https://secwatch.observer/filing/0001104659-26-043497.json
- Plain text: https://secwatch.observer/filing/0001104659-26-043497.txt

## Source-grounded claims
- claim_id: 226ede4975e8cfd7b2f281dc29a2731203c0fe9f
  claim: Traws Pharma, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $10,000,000 (effective 2026-04-15).
  evidence_excerpt: On April 15, 2026, Traws Pharma, Inc. (the “Company”) announced the pricing of an offering (the “Private Placement”) of an aggregate of (i) 5,982,919 shares (the “Purchased Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”) (or, in lieu of Purchased Shares, pre-funded warrants to purchase shares of Common Stock (“Pre-Funded Warrants”)), (ii) Series A warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series A Warrants”), (iii) Series B warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series B Warrants”), and (iv) Series C warrants to initially purchase up to 17,948,757 shares of Common Stock (the “Series C Warrants” and together with the Pre-Funded Warrants, the Series A Warrants and the Series B Warrants, the “Warrants”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) by and between the Company and the purchasers named therein (the “Investors”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465926043497/0001104659-26-043497-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.